Emicizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 857 publications

Balancing hemostasis and thrombosis in aging people with hemophilia

Balancing hemostasis and thrombosis in aging people with hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: June 03, 2026

Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

Journal: Clinics in laboratory medicine

Published: May 15, 2026

Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study

Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study

Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Published: May 14, 2026

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Journal: Seminars in thrombosis and hemostasis

Published: April 14, 2026

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Journal: The Cochrane database of systematic reviews

Published: March 24, 2026

Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study.

Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study.

Journal: Thrombosis journal

Published: March 15, 2026

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

Journal: Journal of medical economics

Published: March 13, 2026

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: March 03, 2026

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.

Journal: Research and practice in thrombosis and haemostasis

Published: February 27, 2026

Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.

Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.

Journal: Expert review of clinical pharmacology

Published: February 23, 2026

Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.

Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.

Journal: Expert review of hematology

Published: February 19, 2026

Procoagulant Effect of FIX Concentrates and Bypass Agents in Combination with Emicizumab and Impact of FVIII Inhibitors.

Procoagulant Effect of FIX Concentrates and Bypass Agents in Combination with Emicizumab and Impact of FVIII Inhibitors.

Journal: Biomedicines

Published: February 12, 2026

Showing 1-12 of 857

Last Updated: 06/30/2026